Supplementary Figure 1. (A) Comparison of TC level at baseline to that at 48 weeks in the TAF (n=140) and non-HBV-infected control (n=560) groups. (B) Comparison of TC levels at baseline to that at 48 weeks in the TDF (n=368) and non-HBV-infected control groups (n=1,472). (C) Comparison of TC level at baseline to that measured at 24 and 48 weeks in the TAF (n=92) and TDF groups (n=276). TC, total cholesterol; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; HBV, hepatitis B virus.